Lumos Pharma, Inc. Common Stock
LUMO
LUMO was delisted on the 11th of December, 2024.
33 hedge funds and large institutions have $8.05M invested in Lumos Pharma, Inc. Common Stock in 2023 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 7 increasing their positions, 12 reducing their positions, and 2 closing their positions.
2% more capital invested
Capital invested by funds: $7.9M → $8.05M (+$157K)
3% less funds holding
Funds holding: 34 → 33 (-1)
42% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 12
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
+$295K |
| 2 |
GWM
Greenwich Wealth Management
Greenwich,
Connecticut
|
+$85.2K |
| 3 |
LPC
Lion Point Capital
New York
|
+$38.8K |
| 4 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
+$18.7K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
+$8.56K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
Acuitas Investments
Seattle,
Washington
|
-$89.2K |
| 2 |
MA
Minerva Advisors
Bala Cynwyd,
Pennsylvania
|
-$84.7K |
| 3 |
Millennium Management
New York
|
-$49.3K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$20.8K |
| 5 |
MAM
Marquette Asset Management
Minneapolis,
Minnesota
|
-$16.6K |
LUMO Hedge Fund Activity: Q3 2023 in Review
33 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Lumos Pharma, Inc. Common Stock (LUMO) for Q3 2023, worth a combined $8.05M — up 2% from $7.9M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of LUMO and 1 opened new positions — a net loss of 1 holder — while 12 trimmed existing stakes and 7 added.
The largest buyer was Wells Fargo, adding an estimated $295K. The largest seller was Acuitas Investments, cutting an estimated $89.2K.
- 33 institutional investors held Lumos Pharma, Inc. Common Stock (LUMO) as of Q3 2023, down from 34 in Q2 2023.
- Funds reported $8.05M of Lumos Pharma, Inc. Common Stock stock for Q3 2023, up 2% quarter-over-quarter.
- 1 fund opened new Lumos Pharma, Inc. Common Stock positions in Q3 2023 and 2 closed out, a net change of -1 holder.
- The largest Lumos Pharma, Inc. Common Stock buyer in Q3 2023 was Wells Fargo, an estimated $295K added.
- The largest Lumos Pharma, Inc. Common Stock seller in Q3 2023 was Acuitas Investments, an estimated $89.2K sold.
Based on aggregated 13F filings for Q3 2023.